Chengdu Kanghong Pharmaceutical (SHE:002773) was named a proposed winner in China's 12th batch of national centralized drug volume-based procurement for perampanel tablets.
The drug treats partial-onset and primary generalized tonic-clonic seizures in adults and children, according to a Monday filing with the Shenzhen bourse.
Under the program, procurement runs through December 2029.
Shares of the pharmaceutical company were up 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments